Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons
JAMA Pediatrics · 01.09.2026 · 180 (9) · 951
DOI: 10.1001/jamapediatrics.2026.2760 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Pediatrics, erschienen am 01.09.2026. Verfasst von Heather J Zar und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics & Child Health and SA-MRC Unit on Child & Adolescent Health, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Palivizumab, Antiviral Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Clesrovimab is a long-acting monoclonal antibody approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season; data concerning clesrovimab from a second RSV season among children who remain at risk for severe disease are needed.
Objective
To evaluate the safety and tolerability of clesrovimab (105 mg) vs palivizumab in RSV season 1 in infants at increased risk for severe RSV disease. Key secondary objectives include describing the safety of 210 mg of clesrovimab in RSV season 2 in children who remain at increased risk for severe RSV disease, clesrovimab pharmacokinetics, and the incidence of RSV-associated disease. Design, Setting, and Participants SMART (MK-1654-007) was a randomized, partially masked, palivizumab-controlled, phase 3 clinical trial, conducted at 110 sites in 27 countries and territories between November 30, 2021, and November 20, 2025. The population constituted palivizumab-eligible infants, including those with prematurity, chronic lung disease of prematurity, or hemodynamically significant congenital heart disease.
Interventions
Participants, randomized 1:1 and stratified by region and condition, received clesrovimab (105 mg) on day 1 followed by placebo on day 28 or monthly palivizumab (15 mg/kg) up to 5 doses (1 dose per month). Eligible infants received open-label clesrovimab (210 mg) before their second RSV season. Main Outcomes and Measures The primary outcome was the observed proportions of participants experiencing adverse events (AEs) after clesrovimab or palivizumab in season 1.
Results
Overall, 997 infants (500 [50.2%] male; median age, 2.6 [range, 0.0-12.0] months) received clesrovimab, 105 mg (n = 498) or palivizumab (n = 499) in season 1; 276 received clesrovimab, 210 mg open-label in season 2. In season 1, the proportions of participants experiencing AEs were comparable between treatment groups. In season 2, clesrovimab, 210 mg was well tolerated. Incidence rates of RSV-associated medically attended lower respiratory infection (MALRI) were comparable between clesrovimab and palivizumab (3.2% [95% CI, 1.8%-5.2%] and 3.4% [95% CI, 2.0%-5.6%], respectively) through day 150 in season 1; total RSV-associated MALRI incidence through day 180 after a 210-mg dose in season 2 was 7.3% (95% CI, 4.4%-11.4%). Conclusions and Relevance In this randomized clinical trial, clesrovimab was well tolerated in infants at increased risk for severe RSV disease through 2 RSV seasons. These findings support the use of clesrovimab in children who remain at risk for severe RSV disease in their second RSV season. Trial Registration ClinicalTrials.gov Identifier: NCT04938830
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics & Child Health and SA-MRC Unit on Child & Adolescent Health, University of Cape Town, Cape Town, South Africa.
- UMC Utrecht, Utrecht, the Netherlands.
- ReSViNET Foundation, Zeist, the Netherlands.
- Yale University, New Haven, Connecticut.
- University Hospital Degli Infermi, Ponderano, Italy.
- Univeristy of Torino, Torino, Italy.
Zitieren
APA
Zar, H. J., Bont, L. J., Manzoni, P., Muñoz, F. M., Ramilo, O., Chen, P. Y., Novoa, J. M., Ordoñez, G. A., Tsolia, M., Tapiéro, B., Acuña-Ávila, M. I., Castellanos, J. M., Meyer, M., Morioka, I., Heinonen, S., Chen, Z., Zeng, T., Railkar, R. A., Arriola, C. S., …, & SMART (MK-1654-007) study group (2026). Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons. JAMA Pediatrics, 180(9), 951. https://doi.org/10.1001/jamapediatrics.2026.2760
Vancouver
Zar HJ, Bont LJ, Manzoni P, Muñoz FM, Ramilo O, Chen PY, et al. Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons. JAMA Pediatrics. 2026;180(9):951. doi:10.1001/jamapediatrics.2026.2760
BibTeX
@article{Zar2026,
author = {Zar, Heather J and Bont, Louis J and Manzoni, Paolo and Muñoz, Flor M and Ramilo, Octavio and Chen, Po-Yen and Novoa, José M and Ordoñez, Gustavo A and Tsolia, Maria and Tapiéro, Bruce and Acuña-Ávila, Mirta I and Castellanos, Javier M and Meyer, Michael and Morioka, Ichiro and Heinonen, Santtu and Chen, Ziqiang and Zeng, Tiantian and Railkar, Radha A and Arriola, Carmen Sofia and Zang, Xiaowei and Hildebrand, Christine and Maestri, Alvino and Castagnini, Luis A and Sinha, Anushua and SMART (MK-1654-007) study group, SMART (MK-1654-007) study group},
title = {Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons},
journal = {JAMA Pediatrics},
year = {2026},
volume = {180},
number = {9},
pages = {951},
doi = {10.1001/jamapediatrics.2026.2760}
}
EUVIMED